These 11 significant hits include 2 flavonols (F2 and F3), 7 chalcones (C1, C2, C3, C6, C8, C11, and C12), a flavonoid analog (A3) and 1 FDA-approved drug (P1) known as Niraparib, which is a PARP-1 inhibitor notably prescribed for advanced ovarian cancers. Here, PARP1 is linked to ovarian carcinoma.